Page last updated: 2024-11-11

gt 2331

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole: the (1R,2R)-isomer is more potent than the (1S,2S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450822
CHEMBL ID2106003
MeSH IDM0296248
PubMed CID6450823
CHEMBL ID278462
SCHEMBL ID7069804
MeSH IDM0296248

Synonyms (54)

Synonym
D03518
perceptin (tn)
223420-20-0
cipralisant maleate (usan)
cipralisant maleate
4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole
gt 2331
7eni812szs ,
1h-imidazole, 4-((1r,2r)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl)-, (2z)-2-butenedioate (1:1)
perceptin
cipralisant maleate [usan]
4-((1r,2r)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl)imidazole maleate (1:1)
unii-7eni812szs
gt2331 ,
CHEMBL2106003
4-[(1r,2r)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]imidazole maleate (1:1)
gt-2331 maleate
223420-20-0 (maleate)
Q27268166
4-((1r,2r)-2-(5,5-dimethylhex-1-yn-1-yl)cyclopropyl)-1h-imidazole maleate
MS-25005
cipralisant (maleate)
HY-106993A
(z)-but-2-enedioic acid;5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole
CS-0103027
AKOS040748137
4-[(1r,2r)-2-(5,5-dimethyl-hex-1-ynyl)-cyclopropyl]-1h-imidazole
bdbm50074629
gtpl1244
4-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-3h-imidazole
cipralisant [inn]
cipralisant
cipralisant, (-)-
CHEMBL278462 ,
gt-2331
(-)-gt-2331
5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole
bdbm50222968
309713xskw ,
unii-309713xskw
4-((1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl)-1h-imidazole
213027-19-1
1h-imidazole, 5-((1r,2r)-2-(5,5-dimethyl-1-hexyn-1-yl)cyclopropyl)-
5-((1r,2r)-2-(5,5-dimethyl-1-hexyn-1-yl)cyclopropyl)-1h-imidazole
SCHEMBL7069804
(1r,2r)-4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole
CVKJAXCQPFOAIN-VXGBXAGGSA-N
CS-0027076
HY-106993
(1r,2r)-4-(2-(5,5-dimethylhex-1-inyl)-cyclopropyl)imidazol
Q909387
MS-23190
DTXSID501318142
AKOS040741554
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H3 receptorRattus norvegicus (Norway rat)Ki0.00020.00010.29638.5110AID692493; AID89707; AID89740; AID89742
Histamine H3 receptorHomo sapiens (human)Ki0.00310.00010.33998.5110AID408541; AID86610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1346017Rat H3 receptor (Histamine receptors)2002European journal of pharmacology, Oct-18, Volume: 453, Issue:1
Characteristics of recombinantly expressed rat and human histamine H3 receptors.
AID1346107Human H3 receptor (Histamine receptors)2002European journal of pharmacology, Oct-18, Volume: 453, Issue:1
Characteristics of recombinantly expressed rat and human histamine H3 receptors.
AID86610Binding affinity for human recombinant H3 receptor2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.
AID89740Binding affinity of compound against Histamine H3 receptor1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID89730Binding affinity for Histamine H3 receptor1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
AID692493Binding affinity to rat cortical histamine H3 receptor2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Histamine H3 receptor as a drug discovery target.
AID89742Binding affinity towards rat cortical H3 receptor2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.
AID89707Binding affinity at histamine H3 receptor in rat cortical membranes by [3H]Nalpha-methylhistamine displacement.1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
AID408541Displacement of [3H]N-alpha-methylhistamine from human histamine H3 receptor expressed in CHO cells2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
AID89716In vitro inhibitory activity against Histamine H3 receptor for K+ evoked depolarization-induced release of [3H]histamine from synaptosomes of rat cerebral cortex2000Bioorganic & medicinal chemistry letters, Oct-16, Volume: 10, Issue:20
Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists.
AID88633In vivo Histamine H3 receptor antagonism, dose required to increase in N-t-methylhistamine levels in Swiss mice brains 90 min after p.o. administration2000Bioorganic & medicinal chemistry letters, Oct-16, Volume: 10, Issue:20
Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (28.57)18.2507
2000's9 (64.29)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.46 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]